Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palivizumab + Ribavirin for RSV Pneumonia in BMT Patients
NCT00014391Phase 3Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 1999
- Primary completion
- Oct 2001
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus pneumonia comparing Palivizumab + Ribavirin with Placebo + Ribavirin (2 arms). Primary endpoint: All-cause mortality reduction at 28 days. Started Feb 1999; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus pneumonia
Beyond the preview
Go deeper on NCT00014391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014391.